Abstract
The aim of this study was to compare the differences in the levels of a highly sensitive cardiac troponin T (Hs-cTnT) between Losartan (LOS) plus hydrochlorothiazide (HCTZ) and amlodipine. Seventy-eight hypertensive patients were randomized to receive LOS/HCTZ or amlodipine for 8 weeks. Both treatments decreased clinic and 24-hour blood pressure to the same extent. The Hs-cTnT level was significantly reduced in the amlodipine group (P < .05), but such a reduction was not found in the LOS/HCTZ group in the upper half group of Hs-cTnT level at baseline. Amlodipine had a more beneficial effect than LOS/HCTZ in patients with high Hs-cTnT levels.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Amlodipine / therapeutic use
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use
-
Antihypertensive Agents / therapeutic use*
-
Biomarkers / blood
-
Blood Pressure / drug effects
-
Calcium Channel Blockers / therapeutic use
-
Drug Combinations
-
Female
-
Humans
-
Hydrochlorothiazide / therapeutic use
-
Hypertension / blood*
-
Hypertension / drug therapy*
-
Hypertension / physiopathology
-
Losartan / therapeutic use
-
Male
-
Middle Aged
-
Natriuretic Peptide, Brain / blood
-
Troponin T / blood*
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Antihypertensive Agents
-
Biomarkers
-
Calcium Channel Blockers
-
Drug Combinations
-
Troponin T
-
hydrochlorothiazide, losartan drug combination
-
Hydrochlorothiazide
-
Natriuretic Peptide, Brain
-
Amlodipine
-
Losartan